title: [Characterization of antirubella vaccine in an epidemiological trial].
abstract: The work was aimed at the evaluation of the antigenic activity and reactogenicity of antirubella vaccine, manufactured by the Serum Institute of India, on the basis of the active observation of 373 children. Vaccinal reactions were registered in 8.8% of the vaccinees. Seroconversion after the injection of the vaccine was 100%. The results of the epidemiological trial demonstrated that the Indian antirubella vaccine was faintly reactogenic and had high antigenic activity.
authors.forename: V F
authors.initials: VF
authors.lastname: Popov
authors.forename: T N
authors.initials: TN
authors.lastname: Iunasova
authors.forename: L A
authors.initials: LA
authors.lastname: Gaĭderova
authors.forename: L A
authors.initials: LA
authors.lastname: Aksenov
authors.forename: O B
authors.initials: OB
authors.lastname: Averina
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Shitikova
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D000918:Antibody Specificity; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007223:Infant; D012409:Rubella / Q000097:blood / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D012412:Rubella virus / Q000276:immunology*; D012426:Russia; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D012411:Rubella Vaccine